Emerging pathways and future targets for the molecular therapy of pancreatic cancer
| العنوان: | Emerging pathways and future targets for the molecular therapy of pancreatic cancer |
|---|---|
| المؤلفون: | Alain Gelibter, Davide Melisi, Federica Cuppone, Emilio Bria, Vanja Vaccaro, Giampaolo Tortora, Francesco Cognetti, Michele Milella, Ludovica Ciuffreda, Maria Simona Pino |
| المصدر: | Expert Opinion on Therapeutic Targets. 15:1183-1196 |
| بيانات النشر: | Informa Healthcare, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Notch, Angiogenesis, medicine.medical_treatment, pancreatic cancer, Clinical Biochemistry, targeted therapy, molecular pathways, medicine.disease_cause, Bioinformatics, Targeted therapy, Hedgehog Proteins, metabolism, Humans, NF-kappa B, metabolism, Pancreatic Neoplasms, genetics/metabolism/therapy, Receptors, metabolism, Signal Transduction, Somatomedins, metabolism, Transforming Growth Factor beta, metabolism, Somatomedins, Transforming Growth Factor beta, Pancreatic cancer, Receptors, Drug Discovery, medicine, Humans, Hedgehog, Pharmacology, Receptors, Notch, genetics/metabolism/therapy, business.industry, Early disease, NF-kappa B, medicine.disease, Molecular therapy, Pancreatic Neoplasms, Immunology, Molecular Medicine, Cancer development, KRAS, Signal Transduction, business |
| الوصف: | Pancreatic cancer treatment remains a challenge for clinicians and researchers. Despite undisputable advances in the comprehension of the molecular mechanisms underlying cancer development and progression, early disease detection and clinical management of patients has made little, if any, progress in the past 20 years. Clinical development of targeted agents directed against validated pathways, such as the EGF/EGF receptor axis, the mutant KRAS protein, MMPs, and VEGF-mediated angiogenesis, alone or in combination with gemcitabine-based standard chemotherapy, has been disappointing.This review explores the preclinical rationale for clinical approaches aimed at targeting the TGF-β, IGF, Hedgehog, Notch and NF-κB signaling pathways, to develop innovative therapeutic strategies for pancreatic cancer.Although some of the already clinically explored approaches (particularly EGFR and KRAS targeting) deserve further clinical consideration, by employing more innovative and creative clinical trial designs than the gemcitabine-targeted agent paradigm that has thus far invariably failed, the targeting of emerging and relatively unexplored signaling pathways holds great promise to increase our understanding of the complex molecular biology and to advance the clinical management of pancreatic cancer. |
| تدمد: | 1744-7631 1472-8222 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d54cb0943b6966431e7f8a4f7cac8bbTest https://doi.org/10.1517/14728222.2011.607438Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6d54cb0943b6966431e7f8a4f7cac8bb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447631 14728222 |
|---|